High Viral Load and Respiratory Failure in Adults Hospitalized for Respiratory Syncytial Virus Infections

Nelson Lee, Martin C W Chan, Grace C Y Lui, Ran Li, Rity Y K Wong, Irene M H Yung, Catherine S K Cheung, Eugenia C Y Chan, David S C Hui, Paul K S Chan, Nelson Lee, Martin C W Chan, Grace C Y Lui, Ran Li, Rity Y K Wong, Irene M H Yung, Catherine S K Cheung, Eugenia C Y Chan, David S C Hui, Paul K S Chan

Abstract

A prospective study among adults hospitalized for polymerase chain reaction-confirmed respiratory syncytial virus infections (n = 123) showed frequent occurrence of lower respiratory-tract complications causing respiratory insufficiency (52.8%), requirement for assisted ventilation (16.3%), and intensive care unit admission/death (12.2%). High viral RNA concentration was detected at time of hospitalization, including in patients who presented later than 2 days of illness (day 1-2, 7.29 ± 1.47; day 3-4, 7.28 ± 1.41; day 5-8, 6.66 ± 1.87 log10 copies/mL). RNA concentration was independently associated with risk of complications and respiratory insufficiency (adjusted odds ratio 1.40 per log10 copies/mL increase, 95% confidence interval, 1.03-1.90; P = .034). Our data indicate the need and provide a basis for clinical research on antiviral therapy in this population.

Keywords: RSV; respiratory failure; viral load.

© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
RSV RNA concentration at time of presentation, shown according to presence (gray box-plot) or absence (white box-plot) of underlying major comorbidities. Dotted line indicates the 25th percentile of viral RNA concentration in this cohort (6.49 log10 copies/mL); day 1 (n = 44), day 2 (n = 36), day 3–4 (n = 27), day 5–8 (n = 16). “Major comorbidities,” as defined in the Charlson Index (see Table 1). Specimen used for diagnosis: nasopharyngeal aspirate, n = 99; nasopharyngeal flocked swab, n = 24; RNA concentrations measured were not significantly different. Abbreviations: cp, copies; RSV, respiratory syncytial virus.

References

    1. Lee N, Qureshi ST. Other viral pneumonias: coronavirus, respiratory syncytial virus, adenovirus, hantavirus. Crit Care Clin 2013; 29:1045–68.
    1. Lee N, Lui GC, Wong KT et al. . High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57:1069–77.
    1. Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis 2007; 195:1046–51.
    1. DeVincenzo JP, Wilkinson T, Vaishnaw A et al. . Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010; 182:1305–14.
    1. Hasegawa K, Jartti T, Mansbach JM et al. . Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland. J Infect Dis 2015; 211:1550–9.
    1. van Elden LJ, van Loon AM, van der Beek A et al. . Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults. J Clin Microbiol 2003; 41:4378–81.
    1. Falsey AR, Formica MA, Treanor JJ, Walsh EE. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol 2003; 41:4160–5.
    1. Lee N, Leo YS, Cao B et al. . NAI treatment, superinfection, and corticosteroids affect survival of influenza patients. Eur Respir J 2015; 10.1183/09031936.00169714.
    1. Lee N, Chan PK, Hui DS et al. . Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492–500.
    1. Pickles RJ, DeVincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol 2015; 235:266–76.
    1. Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis 2013; 207:1424–32.
    1. Duncan CB, Walsh EE, Peterson DR et al. . Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis 2009; 200:1242–6.
    1. Bagga B, Woods CW, Veldman TH et al. . Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. Antivir Ther 2013; 18:785–91.
    1. DeVincenzo JP, Whitley RJ, Mackman RL et al. . Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371:711–22.
    1. Simões EA, DeVincenzo JP, Boeckh M et al. . Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015; 211(suppl 1):S1–20.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj